SEC Tracker
Get the app

Merck MRK

Merck Q1 FY24: revenue $15.8B; diluted EPS $1.87

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers Merck reported for Q1 FY24, the quarter ended Mar 31, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$15.8BNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income$4.8BNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Diluted EPS$1.87No year-earlier figure tagged10-Q income statement, on EDGAR
  4. Cash and cash equivalents$5.6BNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  5. Cash from operations$3.1BNo year-earlier figure tagged10-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Merck files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float over $2B, nearest public float first, as each company reports it on its annual report cover.

  1. Abbott Laboratories ABT public float $232.2B, Jun 30, 2025
  2. Pfizer PFE public float $138.0B, Jun 29, 2025
  3. Vertex Pharmaceuticals VRTX public float $113.4B, Jun 30, 2025
  4. Bristol Myers Squibb BMY public float $94.2B, Jun 30, 2025
  5. Regeneron Pharmaceuticals REGN public float $54.8B, Jun 30, 2025